Source: Annual Congress 2003 - Non-steroidal drugs in the treatment of respiratory diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Hauns, A. Huennemeyer, L. Duursema, D. Hauschke, K. Zech, J. Terblanché, L. Venter, T. D. Bethke (Konstanz, Germany; Bloemfontein, Rivonia, South Africa). Roflumilast and its active metabolite roflumilast N-oxide do not interact with R- and S-warfarin. Eur Respir J 2003; 22: Suppl. 45, 717

Member's Comments

No comment yet.

Related content which might interest you: Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide are not influenced by erythromycin Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004 Effect of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006 Effects of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide Source: Annual Congress 2009 - New bronchodilators Year: 2009 Effects of steady-state female hormones on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 ‘Total PDE4 inhibitory activity‘: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006 Pharmacokinetic characteristics of roflumilast and its active metabolite roflumilast-N-oxide are not affected by food intake Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002 Pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single, oral dose of 500µg roflumilast in the morning versus evening Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003 Equivalent pharmacokinetics of the active metabolite of ciclesonide when using the ciclesonide-MDI with and without a spacer Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004 Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001 No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor Source: International Congress 2017 – Asthma management Year: 2017 Pharmacokinetics of roflumilast and its active metabolite roflumilast-N-oxide in middle aged and young subjects Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002 Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Roflumilast N-oxide, a selective PDE4 inhibitor, curbs platelet-leukocyte interactions Source: Annual Congress 2011 - Translational models of disease Year: 2011 Roflumilast N-oxide reduces human fibroblast function Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 Angiogenic activity of NSCLC cells is inhibited by sulindac and sulphone metabolite of sulindac Source: Eur Respir J 2001; 18: Suppl. 33, 234s Year: 2001 Comparison of pharmacological and pharmacokinetic properties of levocetirizine and dextrocetirizine, the (R) and (S) enantiomers of cetirizine Source: Eur Respir J 2004; 24: Suppl. 48, 129s Year: 2004 Influence of food intake on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 42s Year: 2001 First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001